Novo Nordisk appointed Poul Weihrauch of Mars as a board observer to strengthen its U.S. obesity market strategies. The move aligns with other board changes aimed at enhancing consumer-driven approaches. The company focuses on new distribution channels and direct-to-consumer access for weight-loss drug Wegovy.
Novo Nordisk's Strategic Appointment: Blending Candy Insights with Obesity Treatment
